This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Chinook Therapeutics Valuation
Is 290A undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 290A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 290A's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 290A's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 290A?
Key metric: As 290A barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
The above table shows the Price to Book ratio for 290A. This is calculated by dividing 290A's market cap by their current
book value.
What is 290A's PB Ratio?
PB Ratio
8.1x
Book
US$357.04m
Market Cap
US$2.90b
290A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Book vs Industry: 290A is expensive based on its Price-To-Book Ratio (8.1x) compared to the European Biotechs industry average (2.4x)
Price to Book Ratio vs Fair Ratio
What is 290A's PB Ratio
compared to its
Fair PB Ratio?
This is the expected PB Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
290A PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio
8.1x
Fair PB Ratio
n/a
Price-To-Book vs Fair Ratio: Insufficient data to calculate 290A's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst 290A forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Dec ’25
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Nov ’25
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Oct ’25
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Sep ’25
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Aug ’25
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Jul ’25
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Jun ’25
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
May ’25
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Apr ’25
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Mar ’25
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Feb ’25
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Jan ’25
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Dec ’24
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Nov ’24
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Oct ’24
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Sep ’24
n/a
€36.58
0%
9.4%
€42.88
€27.37
n/a
11
Aug ’24
€35.40
€36.46
+3.0%
9.4%
€42.74
€27.28
n/a
11
Jul ’24
€35.00
€35.90
+2.6%
12.1%
€43.06
€27.49
n/a
11
Jun ’24
€22.40
€33.32
+48.7%
17.6%
€46.45
€27.32
n/a
12
May ’24
€18.00
€33.83
+87.9%
18.1%
€46.42
€27.30
n/a
12
Apr ’24
€21.00
€34.81
+65.8%
18.1%
€47.77
€28.10
n/a
12
Mar ’24
€21.20
€34.80
+64.2%
18.8%
€48.21
€28.36
n/a
11
Feb ’24
€22.80
€33.37
+46.3%
20.6%
€48.62
€26.69
n/a
9
Jan ’24
€24.00
€33.37
+39.0%
20.6%
€48.62
€26.69
n/a
9
Dec ’23
€21.00
€34.25
+63.1%
20.9%
€49.03
€26.92
n/a
8
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2023/08/11 14:27
End of Day Share Price
2023/08/10 00:00
Earnings
2023/06/30
Annual Earnings
2022/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chinook Therapeutics, Inc. is covered by 11 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.